Assessment of Adipocyte Transduction Using Different AAV Capsid Variants

被引:0
|
作者
Boychenko, Stanislav [1 ]
Abdullina, Alina [1 ]
Laktyushkin, Viktor S. [2 ]
Brovin, Andrew [1 ]
Egorov, Alexander D. [1 ]
机构
[1] Sirius Univ Sci & Technol, Sci Ctr Translat Med, Gene Therapy Dept, Sirius 354340, Russia
[2] Sirius Univ Sci & Technol, Resource Ctr Cell Technol, Lab Complex, Sirius 354340, Russia
基金
俄罗斯科学基金会;
关键词
adeno-associated virus; viral tropism; adipocytes; adipose tissue; anti-obesity agents; gene therapy; ADIPOSE-TISSUE; VECTORS; TARGET;
D O I
10.3390/ph17091227
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background/Objectives: Adeno-associated viruses (AAVs) are widely used as viral vectors for gene delivery in mammalian cells. We focused on the efficacy of the transduction of AAV2/5, 2/6, 2/8 and 2/9 expressing GFP in preadipocyte cells by live imaging microscopy using IncuCyte S3 and flow cytometry. Methods: Three transduction modes in 3T3-L1 preadipocyte cells assessed: AAV transduction in 3T3-L1 preadipocyte cells, transduction with further differentiation into mature adipocyte-like cells and the transduction of differentiated 3T3-L1 adipocytes. For the in vivo study, we injected AAV2/6, AAV2/8 and AAV2/9 in adipose tissue of C57BL6 mice, and the transduction capacity of AAV2/6, along with AAV2/8 and AAV2/9 was evaluated. Results: AAV2/6 demonstrated the highest transduction efficiency in 3T3-L1 preadipocytes, as it was 1.5-2-fold more effective than AAV2/5, and AAV2/8 in the range of viral concentrations from 2 x 104 to 1.6 x 105 VG/cell. AAV2/5 and AAV2/8 showed transduction efficiencies similar to each other. The expression of GFP under the CMV promoter remained stable for up to 20 days. The induction of 3T3-L1 differentiation in three days after AAV transduction did not alter the GFP expression level, and AAV2/6 showed the best transduction efficiency. AAV2/6 demonstrated the ability to transduce mature adipocytes. These results were confirmed by in vivo studies on C57BL6 mice. AAV2/6 had the highest transducing activity on both inguinal and interscapular adipose tissue. Conclusions: Thus, AAV2/6 has demonstrated higher transduction efficacy compared to AAV2/5, AAV2/8 and AAV2/9 both in 3T3-L1 adipocytes and adipose tissue in vivo, which proves its usability along with AAV2/8 and AAV2/9 for gene delivery to adipocytes.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Increased Striatum Transduction with an Engineered AAV Capsid and Selective Transduction of Striatal Cholinergic Neurons Using a Truncated Human Choline Acetyltransferase Promoter
    Santoscoy, Miguel C.
    Espinoza, Paula
    De La Cruz, Demitri
    Mahamdeh, Mohammed
    Starr, Jacqueline R.
    Patel, Nikita
    Maguire, Casey A.
    MOLECULAR THERAPY, 2023, 31 (04) : 455 - 456
  • [22] Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS
    Sandoval, Ivette M.
    Kelley, Christy M.
    Bernal-Conde, Luis Daniel
    Steece-Collier, Kathy
    Marmion, David J.
    Davidsson, Marcus
    Crosson, Sean M.
    Boye, Sanford L.
    Boye, Shannon E.
    Manfredsson, Fredric P.
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (04):
  • [23] Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain
    Chakrabarty, Paramita
    Rosario, Awilda
    Cruz, Pedro
    Siemienski, Zoe
    Ceballos-Diaz, Carolina
    Crosby, Keith
    Jansen, Karen
    Borchelt, David R.
    Kim, Ji-Yoen
    Jankowsky, Joanna L.
    Golde, Todd E.
    Levites, Yona
    PLOS ONE, 2013, 8 (06):
  • [24] Characterization of a novel AAV capsid with enhanced brain transduction following systemic delivery
    Glenn, J. D.
    Yost, S.
    Firnberg, E.
    Mercer, A.
    Liu, Y.
    Coruzzi, L.
    Danos, O.
    Bruder, J. T.
    Karumuthil-Melethil, S.
    HUMAN GENE THERAPY, 2019, 30 (11) : A22 - A22
  • [25] Directed evolution of AAV2 yields novel capsid variants
    Maheshri, N
    Kaspar, B
    Schaffer, DV
    MOLECULAR THERAPY, 2004, 9 : S8 - S8
  • [26] High Throughput Production, Purification and Screening Pipelines for AAV Capsid Variants
    Vaidyanathan, Krithika
    Rosenbaum, Adam
    Allen, Olga
    Sprofera, Natalia
    Kunder, Simran
    Nandy, Anisha
    Butler, Brittney
    Cui, Lexie
    Zhao, Siqi
    Boswell, Sarah
    Smith, James Kennon
    Somanathan, Sury
    Maheshri, Narendra
    MOLECULAR THERAPY, 2024, 32 (04) : 686 - 686
  • [27] Development of novel AAV variants for improved transduction of retinal microglia
    Reschigna, A.
    Murenu, E.
    Michalakis, S.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A36 - A36
  • [28] Development of Novel AAV Variants with High Retinal Transduction Efficiency
    Michalakis, Stylianos
    Schoen, Christian
    Pavlou, Marina
    Wagner, Johanna
    Occelli, Laurence
    Petersen-Jones, Simon
    Biel, Martin
    Buening, Hildegard
    MOLECULAR THERAPY, 2019, 27 (04) : 26 - 26
  • [29] Development of novel AAV variants with superior photoreceptor transduction properties
    Michalakis, S.
    Schoen, C.
    Wagner, J.
    Occelli, L.
    Petersen-Jones, S.
    Siedlecki, J.
    Priglinger, S.
    biel, M.
    Buening, H.
    HUMAN GENE THERAPY, 2017, 28 (12) : A75 - A75
  • [30] Engineered AAV9 Variants for Efficient Muscle Transduction
    Li, Shaoyong
    Chen, Shuyuan
    Li, Zhongwan
    Zhang, Runyuan
    Lan, Xing
    Jiang, Yuling
    Zheng, Yanyan
    Wan, Changpeng
    Pang, Xiaodong
    Wang, Lijun
    Ye, Guo-Jie
    Wu, Zhenhua
    MOLECULAR THERAPY, 2023, 31 (04) : 410 - 411